U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Glipizide response

MedGen UID:
322023
•Concept ID:
C1832730
•
Finding
Synonym: Glipizide poor metabolizer
Drug:
Glipizide
MedGen UID:
4900
•Concept ID:
C0017642
•
Pharmacologic Substance
A short-acting, second-generation sulfonylurea with hypoglycemic activity. Glipizide is rapidly absorbed, has a very quick onset of action and a short half-life. This agent is extensively metabolized in the liver and the metabolites as well as the unchanged form are excreted in the urine. [from NCI]
Glipizide
 
Gene (location): G6PD (Xq28)
 
OMIM®: 601130

Professional guidelines

PubMed

Evaluating gliclazide for the treatment of type 2 diabetes mellitus.
Tomlinson B, Li YH, Chan P
Expert Opin Pharmacother 2022 Dec;23(17):1869-1877. Epub 2022 Nov 10 doi: 10.1080/14656566.2022.2141108. PMID: 36300277
Home management of pediatric sulfonylurea ingestions.
Temple C, Hoang R, Kusin S
Clin Toxicol (Phila) 2022 Nov;60(11):1235-1239. Epub 2022 Oct 25 doi: 10.1080/15563650.2022.2125875. PMID: 36282178
The role of sulfonylureas in the treatment of type 2 diabetes.
Tomlinson B, Patil NG, Fok M, Chan P, Lam CWK
Expert Opin Pharmacother 2022 Feb;23(3):387-403. Epub 2021 Nov 10 doi: 10.1080/14656566.2021.1999413. PMID: 34758676

Curated

Gammal et al, Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. 2 Sept 2022. Clin Pharmacol Ther.

DailyMed Drug Label, glipizide, 2022

DailyMed Drug Label, GLIPIZIDE, 2019

Recent clinical studies

Etiology

Encyclopaedic Review of Glipizide Pre-clinical and Clinical Status.
Mohammed S, Mahmood T, Shamim A, Ahsan F, Shariq M, Parveen S, Waseem R, Singh A
Drug Res (Stuttg) 2024 Mar;74(3):123-132. Epub 2024 Feb 26 doi: 10.1055/a-2237-8566. PMID: 38408478
Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH.
Li JH, Brenner LN, Kaur V, Figueroa K, Schroeder P, Huerta-Chagoya A; MAGIC Investigators; Diabetes Prevention Program (DPP) Research Group, Udler MS, Leong A, Mercader JM, Florez JC
Diabetologia 2023 Jul;66(7):1260-1272. Epub 2023 May 26 doi: 10.1007/s00125-023-05922-7. PMID: 37233759Free PMC Article
Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies.
Abdul-Ghani T, Puckett C, Migahid O, Abdelgani S, Migahed A, Adams J, Triplitt C, DeFronzo R, Jayyousi A, Abdul-Ghani M
Diabetes Obes Metab 2022 Sep;24(9):1810-1818. Epub 2022 Jun 29 doi: 10.1111/dom.14767. PMID: 35581905
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB
Clin Pharmacokinet 2005;44(5):467-94. doi: 10.2165/00003088-200544050-00002. PMID: 15871634
Oral antidiabetic drugs: an overview.
Melander A
Diabet Med 1996 Sep;13(9 Suppl 6):S143-7. PMID: 8894498

Diagnosis

Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies.
Abdul-Ghani T, Puckett C, Migahid O, Abdelgani S, Migahed A, Adams J, Triplitt C, DeFronzo R, Jayyousi A, Abdul-Ghani M
Diabetes Obes Metab 2022 Sep;24(9):1810-1818. Epub 2022 Jun 29 doi: 10.1111/dom.14767. PMID: 35581905
Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs.
Xu H, Murray M, McLachlan AJ
Curr Drug Metab 2009 Jul;10(6):643-58. doi: 10.2174/138920009789375388. PMID: 19799532
The role of sulphonylureas in the management of type 2 diabetes mellitus.
Rendell M
Drugs 2004;64(12):1339-58. doi: 10.2165/00003495-200464120-00006. PMID: 15200348
Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 human medulloblastoma cell line.
Miller TR, Taber RD, Molinari EJ, Whiteaker KL, Monteggia LM, Scott VE, Brioni JD, Sullivan JP, Gopalakrishnan M
Eur J Pharmacol 1999 Apr 9;370(2):179-85. doi: 10.1016/s0014-2999(99)00128-4. PMID: 10323267
Oral antidiabetic drugs: an overview.
Melander A
Diabet Med 1996 Sep;13(9 Suppl 6):S143-7. PMID: 8894498

Therapy

Encyclopaedic Review of Glipizide Pre-clinical and Clinical Status.
Mohammed S, Mahmood T, Shamim A, Ahsan F, Shariq M, Parveen S, Waseem R, Singh A
Drug Res (Stuttg) 2024 Mar;74(3):123-132. Epub 2024 Feb 26 doi: 10.1055/a-2237-8566. PMID: 38408478
Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH.
Li JH, Brenner LN, Kaur V, Figueroa K, Schroeder P, Huerta-Chagoya A; MAGIC Investigators; Diabetes Prevention Program (DPP) Research Group, Udler MS, Leong A, Mercader JM, Florez JC
Diabetologia 2023 Jul;66(7):1260-1272. Epub 2023 May 26 doi: 10.1007/s00125-023-05922-7. PMID: 37233759Free PMC Article
Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies.
Abdul-Ghani T, Puckett C, Migahid O, Abdelgani S, Migahed A, Adams J, Triplitt C, DeFronzo R, Jayyousi A, Abdul-Ghani M
Diabetes Obes Metab 2022 Sep;24(9):1810-1818. Epub 2022 Jun 29 doi: 10.1111/dom.14767. PMID: 35581905
Sitagliptin.
Lyseng-Williamson KA
Drugs 2007;67(4):587-97. doi: 10.2165/00003495-200767040-00007. PMID: 17352516
Glipizide: an overview.
Shuman CR
Am J Med 1983 Nov 30;75(5B):55-9. doi: 10.1016/0002-9343(83)90254-1. PMID: 6369968

Prognosis

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
Lavynenko O, Abdul-Ghani M, Alatrach M, Puckett C, Adams J, Abdelgani S, Alkhouri N, Triplitt C, Clarke GD, Vasquez JA, Li J, Cersosimo E, Gastaldelli A, DeFronzo RA
Diabetes Obes Metab 2022 May;24(5):899-907. Epub 2022 Feb 9 doi: 10.1111/dom.14650. PMID: 35014145
Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes.
Abdelgani S, Puckett C, Adams J, Triplitt C, DeFronzo RA, Abdul-Ghani M
J Clin Endocrinol Metab 2021 Nov 19;106(12):3497-3504. doi: 10.1210/clinem/dgab403. PMID: 34343296Free PMC Article
Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study.
Abdelgani S, Puckett C, Adams J, Triplitt C, DeFronzo RA, Abdul-Ghani M
Diabetes Obes Metab 2021 Jul;23(7):1631-1639. Epub 2021 May 6 doi: 10.1111/dom.14383. PMID: 33852204Free PMC Article
Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation.
Strøm Halden TA, Åsberg A, Vik K, Hartmann A, Jenssen T
Nephrol Dial Transplant 2014 Apr;29(4):926-33. Epub 2014 Jan 22 doi: 10.1093/ndt/gft536. PMID: 24452849
Influence of sulfonylureas on the secretion, disposal and effect of insulin.
Almér LO, Johansson E, Melander A, Wåhlin-Boll E
Eur J Clin Pharmacol 1982;22(1):27-32. doi: 10.1007/BF00606421. PMID: 7047169

Clinical prediction guides

Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model.
Urbanova J, Andel M, Potockova J, Klima J, Macek J, Ptacek P, Mat'oska V, Kumstyrova T, Heneberg P
Curr Pharm Des 2015;21(39):5736-48. doi: 10.2174/1381612821666151008124036. PMID: 26446475
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB
Clin Pharmacokinet 2005;44(5):467-94. doi: 10.2165/00003088-200544050-00002. PMID: 15871634
Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 human medulloblastoma cell line.
Miller TR, Taber RD, Molinari EJ, Whiteaker KL, Monteggia LM, Scott VE, Brioni JD, Sullivan JP, Gopalakrishnan M
Eur J Pharmacol 1999 Apr 9;370(2):179-85. doi: 10.1016/s0014-2999(99)00128-4. PMID: 10323267
Pharmacokinetics of glyburide.
Pearson JG
Am J Med 1985 Sep 20;79(3B):67-71. doi: 10.1016/s0002-9343(85)80010-3. PMID: 3931464
Glipizide: an overview.
Shuman CR
Am J Med 1983 Nov 30;75(5B):55-9. doi: 10.1016/0002-9343(83)90254-1. PMID: 6369968

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • CPIC, 2022
      Gammal et al, Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. 2 Sept 2022. Clin Pharmacol Ther.
    • DailyMed Drug Label, 2022
      DailyMed Drug Label, glipizide, 2022
    • DailyMed Drug Label, 2019
      DailyMed Drug Label, GLIPIZIDE, 2019

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • Gene
      Related information in NCBI Gene
    • GTR
      Related information in GTR
    • GTR(Clinical)
      Clinical tests in GTR
    • OMIM
      Related records in OMIM
    • OMIM(Genes)
      OMIM records containing genes associated with phenotypes registered in MedGen
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed
    • PubMed (OMIM)
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...